1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - Expanding the functional and actionable genome: Insights from the study of fusion-driven tumors"}],["$","meta","1",{"name":"description","content":"CCR Grand Rounds \n

\nDr. Caplen co-discovered RNA interference (RNAi) in mammalian cells and has pioneered approaches for exploiting this gene regulatory mechanism to investigate cancer biology and treatment. Dr. Caplen applies the perturbations induced by RNA- or DNA-based technologies to interrogate specific aspects of the genetic, transcriptional, and cell-signaling alterations observed in cancer cells. These functional genetic approaches will be used to enhance our understanding of the mechanistic basis of cancer and to discover new cancer treatment strategies. Current studies are focused on the functional genetic analysis of cancers driven by fusion oncogenes. For more information about the speaker please visit \nhttps://ccr.cancer.gov/Genetics-Branch/natasha-j-caplen\n\n\n\n"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - Expanding the functional and actionable genome: Insights from the study of fusion-driven tumors"}],["$","meta","4",{"property":"og:description","content":"CCR Grand Rounds \n

\nDr. Caplen co-discovered RNA interference (RNAi) in mammalian cells and has pioneered approaches for exploiting this gene regulatory mechanism to investigate cancer biology and treatment. Dr. Caplen applies the perturbations induced by RNA- or DNA-based technologies to interrogate specific aspects of the genetic, transcriptional, and cell-signaling alterations observed in cancer cells. These functional genetic approaches will be used to enhance our understanding of the mechanistic basis of cancer and to discover new cancer treatment strategies. Current studies are focused on the functional genetic analysis of cancers driven by fusion oncogenes. For more information about the speaker please visit \nhttps://ccr.cancer.gov/Genetics-Branch/natasha-j-caplen\n\n\n\n"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/b7e7532a-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/f13b020f-ca8f-4851-9980-e32f2de056f7.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - Expanding the functional and actionable genome: Insights from the study of fusion-driven tumors"}],["$","meta","11",{"name":"twitter:description","content":"CCR Grand Rounds \n

\nDr. Caplen co-discovered RNA interference (RNAi) in mammalian cells and has pioneered approaches for exploiting this gene regulatory mechanism to investigate cancer biology and treatment. Dr. Caplen applies the perturbations induced by RNA- or DNA-based technologies to interrogate specific aspects of the genetic, transcriptional, and cell-signaling alterations observed in cancer cells. These functional genetic approaches will be used to enhance our understanding of the mechanistic basis of cancer and to discover new cancer treatment strategies. Current studies are focused on the functional genetic analysis of cancers driven by fusion oncogenes. For more information about the speaker please visit \nhttps://ccr.cancer.gov/Genetics-Branch/natasha-j-caplen\n\n\n\n"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}